Concentrated two milligrams of intranasal naloxone spray can deliver the drug as effectively as the 0.4-milligram dose given standardly as intramuscular injection in the first fifteen minutes after opioid overdose found a new study published in Addiction journal.
The 2mg spray also maintains blood levels of naloxone more than twice as high as the 0.4mg IM levels for two hours after administration. It should therefore be highly effective in reversing opioid overdose.
Opioid Overdose Risk Factors in Postoperative Patients
A balance must be struck between highly restrictive and overzealous prescribing in order to provide optimal patient care, says study.
Advertisement
‘Naloxone is usually given by injection, but more user-friendly non-injectable alternatives have been developed, including nasal sprays. Take-home naloxone kits can be provided to drug users and other non-medical persons for emergency use’
Tweet it Now
These results support the recent announcement on 14 September 2017 that the European Medicines Agency (EMA) has issued a positive opinion for a 1.8 mg naloxone nasal spray formulation (equivalent to 2mg naloxone hydrochloride), under the brand name Nyxoid.
Take-home naloxone (naloxone kits provided to drug users and other non-medical persons for use in emergency situations) helps to prevent death from heroin/opioid overdose.
![Regulatory Measures On ‘Pill Clinics’ Reduce Opioid Overdose Deaths in Florida]( "Regulatory Measures On ‘Pill Clinics’ Reduce Opioid Overdose Deaths in Florida")
In 2010, Florida passed laws against pill mills, where drug enforcement programs resulted in the arrest and prosecution of doctors operating these clinics.
Naloxone is usually given by injection, but more user-friendly non-injectable alternatives are being developed, including nasal sprays. To be effective, the intranasal spray must be highly concentrated to achieve good absorption, the dose must be adequate but not excessive, and early absorption should be comparable to IM injection.
This study tested nasal naloxone at 1mg, 2mg, and 4mg doses on 38 healthy volunteers, compared with 0.4mg IM and 0.4mg intravenous doses. Each volunteer received all five study treatments, with one naloxone dose per session and each session separated by a washout period.
Blood plasma concentrations of naloxone were measured nineteen times for each volunteer during each treatment session, with intense sampling in the first 15 minutes after dosing.
All three doses of naloxone nasal spray were well absorbed, with the 2mg spray most closely replicating the performance of the 0.4mg IM naloxone injection over the critical first 15 minutes.
The volunteers experienced no severe adverse effects; the main mild adverse effect was a headache, in six volunteers.
Professor Sir John Strang of King's College London, who co-authored the report, is cautiously optimistic: "Our findings demonstrate good early absorption and overall bioavailability of naloxone in healthy subjects, but concentrated naloxone nasal spray has yet to be formally tested in the target population of opioid users.
Nasal naloxone might be absorbed differently by opioid users due to the damaged nasal mucosa, rhinitis, or nasal obstruction from mucus or vomit during the overdose.
Nevertheless, we are very pleased that concentrated nasal naloxone formulations are now receiving regulatory approval and believe that they will help widen the provision of take-home naloxone and thereby save lives."
Source: Eurekalert
Regulatory Measures On ‘Pill Clinics’ Reduce Opioid Overdose Deaths in Florida
In 2010, Florida passed laws against pill mills, where drug enforcement programs resulted in the arrest and prosecution of doctors operating these clinics.
Advertisement
Naloxone is usually given by injection, but more user-friendly non-injectable alternatives are being developed, including nasal sprays. To be effective, the intranasal spray must be highly concentrated to achieve good absorption, the dose must be adequate but not excessive, and early absorption should be comparable to IM injection.
This study tested nasal naloxone at 1mg, 2mg, and 4mg doses on 38 healthy volunteers, compared with 0.4mg IM and 0.4mg intravenous doses. Each volunteer received all five study treatments, with one naloxone dose per session and each session separated by a washout period.
Blood plasma concentrations of naloxone were measured nineteen times for each volunteer during each treatment session, with intense sampling in the first 15 minutes after dosing.
All three doses of naloxone nasal spray were well absorbed, with the 2mg spray most closely replicating the performance of the 0.4mg IM naloxone injection over the critical first 15 minutes.
The volunteers experienced no severe adverse effects; the main mild adverse effect was a headache, in six volunteers.
Professor Sir John Strang of King's College London, who co-authored the report, is cautiously optimistic: "Our findings demonstrate good early absorption and overall bioavailability of naloxone in healthy subjects, but concentrated naloxone nasal spray has yet to be formally tested in the target population of opioid users.
Nasal naloxone might be absorbed differently by opioid users due to the damaged nasal mucosa, rhinitis, or nasal obstruction from mucus or vomit during the overdose.
Nevertheless, we are very pleased that concentrated nasal naloxone formulations are now receiving regulatory approval and believe that they will help widen the provision of take-home naloxone and thereby save lives."
Source: Eurekalert
New Risk Index To Identify Those With Opioid Overdose
Venebio Opioid Advisor (VOA) calculates a patient's likelihood of a life-threatening overdose from a prescription opioid.
Advertisement
 Fatal Opioid Overdose Risk Rises In Medicaid PatientsOpioids are a type of narcotic pain medication. Opioid drugs work by binding to opioid receptors in the brain, spinal cord, and other areas of the body. | Advertisement
|
Advertisement
Recommended Readings
Latest Alcohol & Drug Abuse News
Even with advertising regulations in effect across all four nations, most young individuals still reported encountering e-cigarette promotions.
The United States is currently witnessing its highest overall mortality rates in over a century, driven in part by the surge in drug overdose fatalities.
Deciphering genetic factors in brain responses to METH and COC enables personalized approaches to combat drug abuse.
Giving rats DORA-12 during oxycodone withdrawal reduced future drug-seeking behavior, showing promise for preventing opioid addiction and relapse in humans.
Rising to 9.6% in 2021, daily vaping among New Zealand's 14-year-old students underscores a concerning youth trend.